Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 2/20 | 0.35 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.34 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.34 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.34 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.34 |
| ▸ | ERN1 | O75460 | 1/20 | 0.33 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.33 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.32 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 2/20 | 0.31 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.31 |
| ▸ | MAP4K4 | O95819 | 2/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
| ▸ | CTSK | P43235 | 1/20 | 0.31 |
| ▸ | CTSC | P53634 | 1/20 | 0.31 |
| ▸ | METAP2 | P50579 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL432564 | 0.97 | CHRNB2 (0.35) | PIK3CAPDK1PDK2PDK3PDK4 | |
| SCHEMBL18874134 | 0.87 | PIK3CA (0.33) | PIK3CAPDK1PDK2PDK3PDK4 | |
| SCHEMBL6727328 | 0.87 | PIK3CA (0.33) | PIK3CAPDK1PDK2PDK3PDK4 | |
| SCHEMBL431046 | 0.85 | EDNRB (0.38) | MAP4K4PDE5A | |
| SCHEMBL432196 | 0.84 | S1PR1 (0.34) | — | |
| SCHEMBL15099521 | 0.84 | PIK3CA (0.35) | PIK3CAPDK1PDK2PDK3PDK4 | |
| SCHEMBL12116025 | 0.84 | PIK3CA (0.35) | PIK3CAPDK1PDK2PDK3PDK4 | |
| SCHEMBL18971179 | 0.84 | PIK3CA (0.35) | PIK3CAPDK1PDK2PDK3PDK4 | |
| SCHEMBL431036 | 0.84 | ACACB (0.35) | — | |
| SCHEMBL13065688 | 0.83 | S1PR1 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120065066-A1 | NOVEL HERBICIDES | SYNGENTA CROP PROTECTION LLC (US) | 2012-03-15 | — | — | US | disclosed |
| WO-2010133232-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065066-A1 | NOVEL HERBICIDES | DDT, CYP4X1, CYP1B1 | PIK3CA 2920/4885PDK1 457/4885PDK2 459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.